Metabolic reprogramming regulates macrophage polarization to impact ovarian cancer progression Authors: Meng Zhang, Haizhou Fang, Shuangshuang Yang, Jinxi Yue, Lianlin Zeng, Hong Zhang Published: 2026 ABSTRACT AbstractMetabolic reprogramming and macrophage polarization exhibit a tightly regulated reciprocal interplay, wherein the modulation of energy metabolic pathways and signaling networks directly dictates the functional phenotype and immune responses of macrophages, thereby exerting a critical influence on ovarian cancer progression and therapeutic outcomes. This manuscript elucidates the regulatory mechanisms by which diverse metabolic pathways—including glycolysis, oxidative phosphorylation, and glutamine metabolic reprogramming—orchestrate macrophage polarization. Special emphasis is placed on the functional role of tumor-associated macrophages (TAMs) within the ovarian cancer immune microenvironment, as well as the molecular mechanisms underlying their metabolic regulation. Based on the latest research advances, this study analyzes how metabolic reprogramming modulates the M1/M2 polarization balance to influence tumor immune escape and treatment resistance. Additionally, it summarizes emerging nanoscale strategies for the precise treatment of ovarian cancer via metabolic modulation of macrophage polarization. The overarching aim of this research is to clarify the pivotal role of metabolic regulation in macrophage polarization, thereby providing novel insights and therapeutic strategies for the management of ovarian cancer.Keywords: Metabolic reprogramming, Macrophage polarization, Ovarian cancer, Metabolic pathways, Nanotherapy Introduction Ovarian cancer represents a highly lethal gynecological malignancy, with its dismal survival rate being intrinsically linked to the metabolic adaptability of tumor cells. Within the tumor microenvironment, metabolic alterations not only influence the proliferation and survival of neoplastic cells but also profoundly modulate the functionality and activity of immune cells [1]. Emerging evidence demonstrates that metabolic reprogramming can critically alter macrophage polarization states, thereby impacting tumor initiation and progression [2]. Metabolic reprogramming refers to the phenomenon whereby cells adapt to external stimuli or pathological states by modifying energy metabolic pathways to fulfill functional demands. This intricate process is intimately associated with the pathogenesis and progression of various diseases, including malignancies, immune-mediated inflammatory disorders, and cardiovascular conditions [3]. Encompassing diverse metabolic pathways such as glycolysis, oxidative phosphorylation, and amino acid metabolism, metabolic reprogramming exerts its influence on macrophage polarization by modulating cellular metabolic states. For instance, tumor cells exert immunosuppressive effects by depleting environmental glutamine, thereby attenuating antitumor immune responses [3–5]. Moreover, compelling research has identified specific metabolites (e.g., lactate) as potent inducers of M2 macrophage polarization, fostering an immunosuppressive tumor microenvironment that facilitates malignant progression [6, 7]. Macrophage polarization is a dynamic process in which macrophages differentiate and acquire different functional phenotypes under different microenvironmental stimuli. It is worth noting that TAMs exhibit high heterogeneity. The M1/M2 paradigm merely represents a simplistic framework and cannot fully encompass the continuous spectrum of macrophage states within the body. The M1 macrophages secrete pro-inflammatory cytokines, enhance T-cell activity, and thereby suppress tumor growth, whereas M2 macrophages release immunosuppressive factors and promote angiogenesis, facilitating tumor evasion from immune surveillance [3, 4]. Consequently, elucidating how metabolic reprogramming influences macrophage polarization states holds significant implications for developing novel therapeutic strategies for ovarian cancer. Furthermore, ovarian cancer treatment confronts persistent challenges of immune evasion and drug resistance. The interplay between metabolic reprogramming and macrophage polarization may represent a promising research direction to address these challenges. Emerging evidence demonstrates that targeted interventions in metabolic pathways or key molecules can reshape the tumor microenvironment and augment antitumor immune responses. For instance, the administration of lipid metabolism inhibitors or glutamine metabolic reprogramming inhibitors effectively modulates macrophage polarization, promoting the generation of M1 macrophages and consequently inhibiting tumor growth and metastasis [8, 9]. Here, we summarize the specific mechanisms of metabolic reprogramming in the polarization of macrophages, and elaborate on the latest treatment strategies for ovarian cancer based on these mechanisms. Future research should focus on deeper studies of disease mechanisms and how to utilize the metabolic reprogramming strategy to improve the prognosis and treatment outcomes of ovarian cancer patients, and develop more effective immunotherapy regimens. Literature search strategy Combined with the core theme of this study (the association between metabolic reprogramming, macrophage polarization and ovarian cancer, as well as related therapeutic strategies), PubMed and Web of Science databases were selected for literature search, covering basic experimental studies, clinical studies and review articles. The core theme keywords for search included ovarian cancer, metabolic reprogramming, macrophage polarization, etc. The deadline for literature search was set as September 1, 2025, to ensure the timeliness of the literature cited in this study and fully reflect the latest research progress in this field. The literature screening adopted a three-step method of “initial screening - secondary screening - final confirmation”, which was independently completed by two researchers. When there was a disagreement between the two researchers, a consensus was reached through in-depth discussion. The basic concept of metabolic reprogramming and its role in tumors Metabolic reprogramming is the regulation of metabolic pathways in cells during growth, proliferation, and survival to meet their dynamic energy and biosynthetic needs [10]. Since cancer cells acquire energy and biological macromolecules differently from normal cells, clarifying the role of metabolic reprogramming in cancer is critical for developing new tumor treatment strategies. The main metabolic reprogramming pathways include glycolysis, oxidative phosphorylation, and glutamine metabolic reprogramming. Cancer cells rely on anaerobic glycolysis even under aerobic conditions (the Warburg effect) [11], and glutamine metabolic reprogramming serves as an energy source and participates in biological macromolecule synthesis in cancer cells [12]. These reprogrammed pathways enable cancer cells to adapt to tumor microenvironmental changes (e.g., hypoxia, energy stress), thereby promoting growth and metastasis (Fig. 1 shows the composition and characteristics of the tumor microenvironment) [2, 13–16]. A Components of the TME. The TME comprises cellular and extracellular components. Cellular components mainly include hematopoietic immune cells (TAMs, T cells, B cells, NK cells, DCs, MDSCs) and resident stromal cells (CAFs, ECs, etc.). Extracellular components consist of ECM and cell-secreted proteins (e.g., cytokines, growth factors). Interactions between cancer cells and interstitial cells in the TME regulate tumorigenesis and progression. B Characteristics of the TME. Tumor cells take up large amounts of nutrients (glucose, amino acids, etc.) from the TME to meet substance and energy requirements, leading to a nutrient-poor environment. They undergo aerobic glycolysis to produce and release lactic acid, resulting in an acidic microenvironment. Tumor cell-derived cytokines, chemokines, metabolites, and antigens reprogram interstitial immune cells, forming an immunosuppressive environment characterized by M2-like TAMs, Tregs, MDSCs, etc. Rapid tumor cell proliferation and immature tumor vasculature induce hypoxia Beyond affecting cancer cell growth, metabolic reprogramming alters the immune microenvironment by regulating the metabolic status of immune cells like TAMs, influencing tumor immune escape and treatment response [17]. Tumor cells promote motility and invasiveness via fatty acid accumulation and oxidation [2], and release specific metabolites to modify the microenvironment—for example, excessive glutamine uptake restricts immune cell metabolism [18, 19]. Recent studies showed metabolic reprogramming induces immune cell polarization changes, enhancing the tumor microenvironment’s immunosuppression. For example, TAMs undergo metabolic reprogramming in the tumor microenvironment and transform into tumor-promoting M2 macrophages [20]. Additionally, tumor cell metabolic reprogramming directly impairs T cell function via secreted metabolites, leading to T cell dysfunction and exhaustion [4, 21]. Thus, tumor cell metabolic reprogramming plays a key role in shaping the tumor immune microenvironment and regulating immune cell function and anti-tumor responses. Theoretically, targeting tumor metabolism could restore immune cell function and enhance immunotherapy efficacy. The biological basis and classification of macrophage polarization Metabolic characteristics and functions of M1 macrophages The M1 macrophages play a crucial role in anti-tumor immunity, and their metabolic characteristics mainly rely on glycolysis. In the tumor microenvironment, M1 macrophages can rapidly generate ATP and other important metabolic products through glycolysis [22]. After activation, M1 macrophages enhance the glycolysis pathway by upregulating the expression of related enzymes, such as 6-phosphofructokinase, thereby increasing the production of lactic acid and the formation of an acidic intracellular environment [23]. Furthermore, M1 macrophages can also release various pro-inflammatory factors, such as tumor necrosis factor α (TNF-α), interleukin 6 (IL-6), etc., which further enhances their anti-tumor ability [24, 25]. The metabolic characteristics of M1 macrophages are also reflected in their utilization of amino acids, and in particular, the metabolism of arginine is considered to be closely related to the activity of M1 macrophages [26]. However, the metabolic state of M1 macrophages is not constant. In the tumor microenvironment, certain factors may cause M1 macrophages to transform into M2 macrophages, and this transformation is usually accompanied by changes in metabolic patterns [27]. Therefore, regulating the metabolic reprogramming of M1 macrophages may provide new strategies for cancer treatment. Metabolic characteristics and functions of M2 macrophages M2 macrophages mainly rely on oxidative phosphorylation and fatty acid oxidation to meet their energy requirements. This metabolic characteristic enables them to exert a tumor-promoting effect in the tumor microenvironment [22]. It is noticed that M2 macrophages maintain their functions by enhancing oxidative phosphorylation and secrete various cytokines and growth factors, which promote the proliferation of tumor cells [28]. At the same time, fatty acid oxidation is regarded as another important metabolic pathway for M2 macrophages [29]. Moreover, M2 macrophages can affect the polarization state of tumor-associated macrophages by promoting the activation of specific metabolic pathways, thereby promoting the immune escape of tumor cells in the tumor microenvironment [30]. Studies have confirmed that the accumulation of M2 macrophages is associated with poor prognosis in patients with ovarian cancer, which may be related to the metabolic reprogramming in the tumor microenvironment [31]. For instance, the metabolic reprogramming of M2 macrophages enables them to maintain an immunosuppressive state in the tumor microenvironment, thereby promoting tumor growth and metastasis [32]. Therefore, the metabolic characteristics and functions of M2 macrophages provide a new perspective for understanding the immune regulation in the tumor microenvironment. These findings highlight the potential value of therapeutic strategies targeting the metabolic pathways of M2 macrophages in the treatment of tumors. The mutual regulation between metabolic state and polarization state Macrophages can polarize into M1 or M2 depending on the microenvironment. Changes in metabolic pathways can drive the polarization direction of macrophages, and conversely, changes in the polarization state can regulate the expression of specific metabolic enzymes. M1 macrophages mainly rely on glycolysis as their energy source [23]. In contrast, M2 macrophages obtain energy through pathways such as oxidative phosphorylation [33]. This shift in metabolic pattern involves the release of cytokines and the interaction of gene expression regulation. For instance, alterations in fatty acid metabolism can affect the polarization state of macrophages, and the polarization of M2 macrophages is regulated by fatty acids and their metabolites [33, 34]. During this process, the expression and activity of key metabolic enzymes are also regulated by the polarization state. For instance, in M1 macrophages, enzymes activated through the glycolytic pathway, exhibit significant changes in their expression levels as the polarization state of the macrophages changes [35]. Meanwhile, some important metabolic enzymes in M2 macrophages, are also upregulated or downregulated during their polarization process, thereby influencing their metabolic characteristics and functions [36]. In conclusion, there is a complex interplay between the metabolic state and the polarization state of macrophages. Therefore, by regulating the metabolic pathways of macrophages, it may be possible to effectively change their polarization state, thereby improving the prognosis of diseases [37]. The role of glutamine metabolic reprogramming in macrophage polarization and ovarian cancer As a non-essential amino acid, glutamine plays a crucial role in cellular metabolism, especially macrophage polarization, serving as a nitrogen source to support cellular metabolic pathways and enhance cell survival [38]. In macrophages, it regulates polarization through multiple pathways by enhancing aerobic glycolysis and the tricarboxylic acid (TCA) cycle to potentiate M1 macrophage inflammatory responses to facilitate ATP-citrate lyase-dependent epigenetic reprogramming for activating pro-inflammatory genes and antitumor phenotypes [38]. And it also modulates intracellular redox homeostasis (NAD+/NADH ratio) via lactate conversion and potentiates fatty acid oxidation (FAO) to promote M1 activation [26, 39], while elucidating its mechanisms may provide novel therapeutic strategies for cancer. During M2 polarization, glutamine modulates key metabolic pathways to induce immunosuppression in the tumor microenvironment by enhancing pyruvate dehydrogenase (PDH) activity to sustain oxidative phosphorylation (OXPHOS) and maintain the M2 metabolic profile [39]. In murine models, the glutamine metabolite α-ketoglutarate (αKG) potentiates M2 polarization while glutamine depletion reduces M2 abundance and impairs angiogenesis [40], thereby promoting tumor growth and metastasis [41]. Given glutamine metabolic reprogramming’s role in malignancies, research focuses on developing related inhibitors, among which the glutamine metabolic reprogramming inhibitor 6-diazo-5-oxo-L-norleucine (DON) exerts antitumor effects by suppressing glutaminase (GLS) to impair cancer cell energy production and biosynthesis [41–45]. Despite promising preclinical results, DON faces clinical challenges (poor stability, limited solubility), and researchers are exploring strategies like nanocarrier-based co-encapsulation of DON with other agents to enhance targeting and controlled release, future research focusing on optimizing their clinical applications and combination strategies to maximize efficacy [46, 47]. In conclusion, glutamine metabolic reprogramming inhibitors exhibit broad therapeutic potential in oncology. Future research will prioritize optimizing their clinical applications and combination therapy strategies to maximize their efficacy in cancer treatment. The relationship between metabolic reprogramming and tumor immune evasion The metabolic state of macrophages and the mechanism of immune suppression In the tumor microenvironment, M2 macrophages facilitate immune evasion through multiple mechanisms [48]. Primarily, they directly suppress T-cell activity by secreting immunosuppressive cytokines, thereby attenuating antitumor immune responses. Furthermore, M2 macrophages enhance the immunosuppressive properties of the tumor microenvironment by promoting interactions with tumor-associated stromal cells [49]. During metabolic reprogramming, M2 macrophages upregulate amino acid uptake, activating the mTOR signaling pathway and remodeling lipid and carbohydrate metabolism. These metabolic alterations not only sustain the survival and functionality of M2 macrophages but also foster tumor growth and metastasis via amplified secretion of immunosuppressive factors [50, 51]. Consequently, targeting the metabolic signatures of M2 macrophages may emerge as a novel strategy to enhance the efficacy of cancer immunotherapy [52, 53]. The regulatory role of metabolites in the immune microenvironment In the tumor microenvironment, tumor cells generate copious lactate via rapid glycolysis, leading to microenvironmental acidification. This acidic milieu modulates the function of tumor-associated immune cells through multiple mechanisms [49, 54]. Primarily, lactate influences immune cell polarization states. Elevated lactate concentrations drive macrophages toward M2 polarization within the tumor microenvironment [55]. Furthermore, lactate impairs T-cell effector function by disrupting their metabolic state, culminating in T-cell dysfunction and exhaustion [55]. Furthermore, lactate modulates the expression of immune cell surface receptors while suppressing cytokine secretion, thereby facilitating tumor immune evasion [56]. These findings underscore the therapeutic potential of targeting metabolic byproducts in cancer immunotherapy. Future research should prioritize elucidating mechanisms to counteract lactate-mediated immunosuppression and restore the antitumor functionality of immune cells [57]. Mechanism of treatment resistance mediated by metabolic reprogramming Emerging evidence demonstrates that the metabolic and polarization states of TAMs directly influence tumor immune evasion and chemoresistance [58]. M2 polarization of TAMs markedly enhances tumor cell tolerance to chemotherapeutic agents, particularly by promoting metabolic reprogramming of tumor cells (Fig. 2A) [59, 60]. A Generation and characterization of glyco-GNPs targeting hepatic macrophages. a Schematic protocol: one syringe contains HAuCl4 solution (0.015 × 10⁻³ m), the other AA solution (0.004 × 10⁻³ m); mixing induces HAuCl4 reduction to Au⁰ in the coil. Image created with Biorender. b Chemical composition of GNPs modified with EG6C11SH (PEG), Man, or Sia. c Synthetic scheme of Sia-GNPs: (I) PFP, DMC, EDC, RT, 18 h; (II) 3-Aminopropyl-N-acetylneuraminic acid (DMF), DIPEA, DMC, RT, 36 h; (III) MeOH/MeONa (pH = 9), RT, 1 h. B Schematic of major circulation routes through target organs, with FRβ density scores in each organ The remodeling of metabolic pathways enables TAMs, through interactions with tumor cells, to activate stem-like characteristics via secretion of specific cytokines (e.g., CXCL7), thereby inducing chemoresistance [61, 62]. Metabolic reprogramming not only alters macrophage polarization but also fortifies tumor cell survival and drug resistance by modulating intercellular interactions within the tumor microenvironment. Research targeting this metabolic reprogramming provides a critical theoretical foundation for the development of novel antitumor therapeutic strategies [4, 63] (Fig. 2B). Regulation of metabolic-related signaling pathways in macrophage polarization STAT signaling pathway In macrophage polarization, the signal transducer and activator of transcription (STAT) signaling pathway plays a pivotal role. STAT1 and STAT6 are recognized as key regulators of M1- and M2 macrophage polarization, respectively. Activation of STAT1 promotes glycolysis, which is associated with M1 macrophage polarization, whereas STAT6 activation enhances oxidative phosphorylation, linked to M2 polarization [36, 64]. Furthermore, inhibition of the JAK-STAT signaling pathway effectively modulates macrophage polarization. A polyvinyl alcohol hydrogel incorporating a JAK1 inhibitor suppresses M1 polarization while promoting M2 macrophage activity, thereby improving wound healing outcomes [65]. Consequently, targeting the STAT signaling pathway and its associated metabolic pathways may emerge as a novel therapeutic strategy for malignancies such as ovarian cancer [66]. HIF-1α and regulation of glycolysis In the tumor microenvironment, hypoxia-inducible factor-1α (HIF-1α) functions as a critical transcription factor by activating the expression of glucose transporter 1 and lactate dehydrogenase A (LDHA), thereby driving glycolysis in macrophages. This process not only provides energy support for macrophages but also promotes the secretion of pro-inflammatory cytokines, such as IL-1β and TNF-α, thereby enhancing their immunoresponsiveness [67]. Under hypoxic conditions, HIF-1α expression is markedly upregulated, thereby facilitating M1 polarization of macrophages. Conversely, inhibition of HIF-1α leads to diminished glycolytic capacity and reduced production of M1 cytokines [68]. Additionally, HIF-1α modulates glycolysis through interactions with metabolic enzymes. By downregulating pyruvate dehydrogenase kinase 1 (PDK1) expression, HIF-1α facilitates pyruvate entry into the TCA cycle, thereby influencing the metabolic state of macrophages [69]. This mechanism offers novel insights into macrophage function within the tumor microenvironment and provides a potential foundation for HIF-1α-targeted therapeutic strategies. mTOR signaling pathway Activation of the mTOR pathway is typically associated with M1 polarization. On one hand, exposure to specific environmental stimuli (e.g., fatty acids, LPS, or IFN-γ) triggers mTOR signaling, thereby promoting M1 macrophage polarization by enhancing glycolysis and pro-inflammatory cytokine expression, thereby augmenting macrophage activity [70]. On the other hand, inhibition of mTOR signaling attenuates the inflammatory response of M1 macrophages while facilitating M2 macrophage formation [71]. In the context of ovarian cancer, elevated concentrations of fatty acids in the tumor microenvironment have been demonstrated to promote the transition of macrophages toward M1 polarization by inhibiting mTOR-mediated autophagy [70]. In summary, the mTOR signaling pathway plays a central role in modulating macrophage polarization states, influencing their functional status through metabolic reprogramming [72]. PI3K signaling pathway The phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway is a key regulator of metabolic reprogramming and macrophage polarization, closely involved in the regulation of glucose metabolism, lipid metabolism, and cytokine secretion in macrophages. In the tumor microenvironment of ovarian cancer, various stimuli (e.g., tumor-derived growth factors, cytokines) can activate the PI3K/Akt pathway, thereby modulating the polarization direction of macrophages through regulating metabolic pathways [73, 74]. For M1 macrophage polarization, activation of the PI3K/Akt pathway promotes glycolytic metabolism by upregulating the expression of GLUT1 and key glycolytic enzymes (e.g., hexokinase 2), thereby providing sufficient energy and metabolic intermediates for the secretion of pro-inflammatory cytokines (e.g., IL-1β, TNF-α) and enhancing the anti-tumor immune function of M1 macrophages [75, 76]. In contrast, for M2 macrophage polarization, the PI3K/Akt pathway facilitates oxidative phosphorylation and fatty acid oxidation by activating downstream targets (e.g., mammalian target of rapamycin complex 2), which is essential for maintaining the immunosuppressive phenotype of M2 macrophages and promoting tumor progression [77, 78]. Notably, in ovarian cancer, the abnormal activation of the PI3K/Akt pathway in TAMs is closely related to their M2 polarization and poor prognosis of patients [79]. Inhibition of the PI3K/Akt pathway can effectively reverse the M2 polarization of TAMs, restore their glycolytic capacity, enhance the secretion of pro-inflammatory cytokines, and thereby improve the anti-tumor immune response [80]. Therefore, targeting the PI3K/Akt signaling pathway and its associated metabolic regulatory mechanisms may provide a new target for the treatment of ovarian cancer by modulating macrophage polarization. ERKs signaling pathway The extracellular signal-regulated kinases (ERKs) signaling pathway, a member of the mitogen-activated protein kinase (MAPK) family, is another critical pathway involved in the regulation of macrophage polarization and metabolic reprogramming. ERKs are activated by various extracellular stimuli (e.g., LPS, IFN-γ, and tumor-derived metabolites) and exert regulatory effects on macrophage polarization by modulating metabolic pathways and cytokine expression [81, 82]. In M1 macrophage polarization, activation of the ERKs pathway promotes glycolysis by upregulating the expression of LDHA and enhancing lactate production, which in turn amplifies the pro-inflammatory response of M1 macrophages [83]. Additionally, the ERKs pathway can cooperate with the STAT1 pathway to promote the transcription of pro-inflammatory genes (e.g., iNOS, TNF-α), further reinforcing the M1 phenotype [84]. For M2 macrophage polarization, the ERKs pathway is involved in the regulation of oxidative phosphorylation and arginine metabolism, which is crucial for the secretion of immunosuppressive cytokines (e.g., IL-10, TGF-β) and the maintenance of M2 macrophage function [84]. In the context of ovarian cancer, the ERKs pathway is abnormally activated in TAMs, and its activation is closely associated with the M2 polarization of TAMs and tumor metastasis [85]. Inhibition of the ERKs pathway can effectively suppress M2 polarization of TAMs, reduce the secretion of immunosuppressive factors, and enhance the anti-tumor activity of macrophages [86]. Thus, the ERKs signaling pathway, as an important regulatory node of metabolic reprogramming and macrophage polarization, has potential therapeutic value in ovarian cancer treatment. ERK1/2 activation downstream of CSF-1R/GM-CSFR can promote macrophage proliferation and self-renewal by activating Ets family transcription factors and increasing Cyclin-D and c-Myc expression. MEK5/ERK5 signaling may sustain TAM proliferation by suppressing p21 expression and modulating c-Maf/MafB, Ets2, and Cyclin-D, thereby contributing to the maintenance of tumor-associated macrophage populations within the tumor microenvironment [87] (Table 1). Table 1The summary of the effect of metabolic pathway to macrophage polarizationMetabolicPathwaysEffectRole in Ovarian CancerTherapeutic StrategiesRef.Glycolysis6-phosphofructokinase, HIF-1α, GLUT1, LDHA, PDK1, STAT1, mTOR, ERK1/2、ERK5、CSF-1/CSF-1R–MEK/ERK axisSupports M1 polarization; enhance glycolysis; facilitate M1 polarization; ERKs upregulates LDHAM1 macrophages exert anti-tumor effects; elevated fatty acids promote M1 polarizationTargeting HIF-1α; inhibiting mTOR signaling; targeting ERKs pathway to enhance M1 anti-tumor activity[22, 23, 36, 64, 67–72, 83, 84, 87]Oxidative Phosphorylation (OXPHOS)PDH, STAT6, PI3K/Akt-mTORC2, ERKsSTAT6 activation enhances OXPHOS; PI3K/Akt-mTORC2 facilitates OXPHOSM2 macrophages promote tumor growth, metastasis, and immune escapeInhibiting PI3K/Akt pathway to reverse M2 polarization; targeting ERKs pathway to suppress M2 function[22, 36, 39, 64, 70–72, 77, 78, 84]Fatty Acid Oxidation (FAO)PI3K/Akt-mTORC2Supports M2 polarization; PI3K/Akt-mTORC2 facilitates FAO to maintain M2 phenotypeM2 FAO sustains immunosuppressive tumor microenvironment; elevated fatty acids induce M1 polarizationTargeting fatty acid oxidation to alter TAM polarization; combining with immunotherapy to enhance anti-tumor efficacy[29, 70, 72, 77, 78]Glutamine Metabolic ReprogrammingGLS, PDH, α-ketoglutarate (αKG), DONEnhances M1 inflammatory response; promotes M2 polarizationTumor cells exploit glutamine to drive TAMs toward M2 polarizationUsing DON to suppress GLS[26, 38–47]Lactate MetabolismLDHA, lactateDrives macrophages toward M2 polarization; impairs T-cell functionTumor-derived lactate acidifies microenvironment, facilitates immune evasion and tumor progressionTargeting lactate-mediated immunosuppression; inhibiting LDHA to reduce lactate accumulation[49, 54–57]Metabolic-related Signaling PathwaysSTAT (STAT1/STAT6), JAK-STAT, HIF-1α, mTOR, PI3K/Akt, ERKsM1 polarization (glycolysis); STAT6: M2 polarization (OXPHOS)regulate tumor microenvironment and immune escapeInhibiting PI3K/Akt to reverse M2 polarization; targeting ERKs to suppress M2 polarization[36, 64–86] The summary of the effect of metabolic pathway to macrophage polarization CAR-T cell therapy for ovarian cancer Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a promising immunotherapeutic strategy for cancer, complementing metabolic targeting and traditional immunotherapy. CAR-T cells are engineered to express specific antigens targeting ovarian cancer cells, enabling precise recognition and elimination of tumor cells [88, 89]. Current preclinical and early clinical studies have demonstrated the efficacy of CAR-T therapy in ovarian cancer, particularly in relapsed or refractory cases. However, its clinical application is limited by challenges such as tumor microenvironment immunosuppression, antigen escape, and off-target effects [88]. Combining CAR-T therapy with metabolic targeting strategies can effectively improve CAR-T cell infiltration and anti-tumor activity, addressing the immunosuppressive barrier [90]. Future research should focus on optimizing CAR-T cell design, identifying novel specific antigens, and exploring combination regimens with metabolic regulators or immune checkpoint inhibitors to enhance efficacy and reduce adverse reactions, providing a new therapeutic option for ovarian cancer treatment [91]. Future research directions and clinical application prospects Precise regulation strategies for metabolic reprogramming and macrophage polarization Metabolic reprogramming refers to the process by which cells adjust their metabolic pathways in response to varying environmental conditions. Macrophages can adapt to microenvironmental changes through metabolic reprogramming, thereby transitioning into distinct polarization states [92, 93]. In recent years, advancements in nanomedicine have unlocked novel possibilities for modulating macrophage polarization. For instance, leveraging nanotechnology, targeted modulation of specific signaling pathways (e.g., NF-κB, STAT, TLR) enables precise control over macrophage metabolism [94–97]. A notable example is the M@C-HA/ICG nanodrug developed by Wang et al., which induces M1 macrophage polarization by activating the TLR signaling pathway within macrophages, thereby enhancing their phagocytic capacity and cytokine secretion against tumor cells [98–101]. Additionally, specific metabolic factors such as lactate and its associated lactylation modifications have been demonstrated to modulate macrophage polarization states [102]. Folate-modified silver nanoparticles can effectively target M2 macrophages, thereby promoting polarization (Fig. 3A) [103]. A Schematic of major circulation routes through target organs, with calculated FRβ density scores in each organ. B Tumor microenvironment cholesterol metabolism regulates tumor-infiltrating immune cell function: Tumor-derived cholesterol induces CD8⁺ T cell dysfunction (loss of antitumor activity via inhibitory receptor overexpression) and inhibits Tc9 cell antitumor function (LXR pathway activation, reduced IL-9 expression). Tumor-derived oxysterols downregulate CCR7 in mature DCs, inhibiting their migration to draining lymph nodes and antitumor immunity; bind/activate CXCR2 to recruit neutrophils, which promote tumor growth via massive total MMP-9 release and increased Bv8 mRNA levels; and bind LXR in immune cells to inhibit macrophage activation and promote M2 polarization Metabolic modulation strategies targeting macrophages also include inhibiting specific metabolic pathways—for instance, suppressing glycolysis to promote M2 polarization, restoring M1 macrophage function by enhancing oxidative phosphorylation, and employing CRISPR technology to target the expression of key metabolic enzymes [104–106]. New strategies for combined metabolic targeting and immunotherapy In recent years, the combined strategy of metabolic targeting and immunotherapy has emerged as a new direction in cancer treatment, particularly showing promising results in the treatment of ovarian cancer [38, 107, 108]. Among them, immune checkpoint inhibitors (such as PD-1/PD-L1 inhibitors) have achieved remarkable success in many types of tumors, but their efficacy varies among different patients (Fig. 3B) [4, 109]. In ovarian cancer, tumor-associated macrophages (TAMs) typically exhibit a M2 phenotype, which has immunosuppressive properties. By using metabolic inhibitors (such as inhibitors targeting fatty acid oxidation) to alter the metabolic state of TAMs, thereby enhancing the immune response against the tumor [92, 110]. Additionally, by inhibiting the relevant metabolic pathways, the polarization of M2 macrophages can be effectively suppressed, and the anti-tumor activity of CD8 + T cells can be enhanced, which also provides a theoretical basis for the combined strategy of metabolic targeting and immunotherapy [111]. The report indicates that interventions targeting lipid metabolism can not only alter the polarization state of TAMs, but also enhance the activity of T cells by improving the tumor microenvironment, thereby increasing the response rate to immune checkpoint inhibitors [17, 37]. At the same time, this combined treatment strategy can also reduce the metabolic escape of tumor cells, and thereby improve the overall therapeutic effect [16]. In the actual implementation, the researchers suggest using drugs targeting specific metabolic pathways in combination with immune checkpoint inhibitors, in order to create a more favorable immune state in the tumor microenvironment. This approach can not only achieve more precise targeted therapy but also enhance efficacy and reduce side effects [112–115]. Further studies should explore the interactions between different metabolic pathways and immunotherapy to provide more effective treatment options for clinical practice (Table 2). Table 2Summary table of regulatory strategies for metabolic reprogramming and macrophage polarizationCategoryStrategyMethodMechanismRef.Precise regulation of macrophage polarizationNanotechnology-based regulationEngineer physicochemical properties (particle size, surface charge, composition) of nanomaterials; develop targeted nanodrugs (e.g., M@C-HA/ICG, folate-modified silver nanoparticles)Induce M1 polarization (M@C-HA/ICG via TLR pathway); target M2 macrophages to promote polarization transformation and enhance antitumor immunity [94–101, 103]Signaling pathway targeted modulationTarget specific signaling pathways (e.g., NF-κB, STAT, TLR) to regulate macrophage metabolismPrecisely control macrophage polarization direction by regulating metabolic pathways [94–97]Metabolic factor modulationRegulate metabolic factors (e.g., lactate) and their associated modifications (e.g., lactylation)Modulate macrophage polarization states [102]Metabolic pathway inhibition/regulationSuppress glycolysis; enhance oxidative phosphorylation; use CRISPR technology to target key metabolic enzyme expressionPromote M2 polarization (glycolysis suppression); restore M1 function (oxidative phosphorylation enhancement) [104–106]Combined metabolic targeting and immunotherapyMetabolic inhibitor + TAM polarization regulationUse metabolic inhibitors (e.g., fatty acid oxidation inhibitors) to alter TAM metabolic stateTransform M2 TAMs into M1; enhance anti-tumor immune response; suppress M2 polarization and enhance CD8 + T cell activity [92, 110, 111]Metabolic targeting + immune checkpoint inhibitorsCombine drugs targeting specific metabolic pathways (e.g., lipid metabolism) with PD-1/PD-L1 inhibitorsImprove tumor microenvironment; enhance T cell activity; increase response rate to immune checkpoint inhibitors; reduce tumor metabolic escape [17, 37, 112–117] Summary table of regulatory strategies for metabolic reprogramming and macrophage polarization Conclusion and outlook In recent years, the impact of metabolic reprogramming within the TME has garnered growing attention, particularly in ovarian cancer research, where macrophage polarization has emerged as a pivotal regulatory factor. Modulation of macrophage polarization states can alter the tumor immune microenvironment, thereby exerting a profound influence on ovarian cancer progression. This discovery not only provides novel insights into the mechanisms underlying tumor metabolic adaptation but also lays a solid foundation for the development of innovative therapeutic strategies. Future research directions should focus on integrated approaches combining metabolic modulation with immunotherapy. Such interdisciplinary collaboration holds significant promise for overcoming the current bottleneck of drug resistance in ovarian cancer treatment, enabling more precise therapeutic outcomes. By elucidating the intricate interplay between metabolic and immune regulatory mechanisms, we can not only establish a robust theoretical framework for therapeutic innovation in ovarian cancer but also explore opportunities for clinical translation to other tumor types. Despite substantial progress in delineating the relationship between metabolic reprogramming and tumor immune evasion, controversies persist regarding the specific molecular mechanisms and pathway interactions across different studies. Future research must validate these findings in diverse experimental models and clinical samples to better comprehend the complex crosstalk between metabolism and immunity. Additionally, reconciling discrepancies among varying research outcomes will be a critical challenge for advancing this field. In summary, in-depth exploration of macrophage polarization and metabolic reprogramming may facilitate the development of more effective intervention strategies for ovarian cancer treatment in the future. In the face of the dynamically evolving tumor microenvironment, nanodrugs targeting metabolic pathways and integrated immunotherapy strategies offer new hope for improving patient survival rates and quality of life. We anticipate further breakthroughs in this field, which will ultimately provide patients with superior therapeutic options. Abbreviations Cancer-associated fibroblasts Dendritic cells Endothelial cells Extracellular matrix Myeloid-derived suppressor cells Natural killer cells Tumor-associated macrophages X-box binding protein 1 Lymphocyte-activation gene 3 T cell immunoglobulin-3 Programmed death-1 Cytotoxic T 9 cells Endoplasmic reticulum Liver X receptor CXC receptor 2 Matrix metalloprotein-9 Chemokine receptor type 7 Author contributions Meng Zhang and Haizhou Fang: Data analysis, Writing - original draft. Shuangshuang Yang and Jinxi Yue: Data analysis, Methodology, Supervision, Images analysis. Lianlin Zeng: Writing – review & editing. Hong Zhang: Conceptualization, Methodology, Supervision, Funding acquisition. All authors participated in this article. Funding Not applicable. Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Meng Zhang and Haizhou Fang have contributed equally to this work. Contributor Information Lianlin Zeng, Email: lianlin4886@163.com. Hong Zhang, Email: zhanghong4862026@163.com. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.